Consensus QuidelOrtho Corporation

Equities

QDEL

US2197981051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 21:00:00 12/12/2025 GMT			5-day change	1st Jan Change
28.80 ^USD	-2.90%		+3.75%	-35.35%

12-03	QuidelOrtho Corporation Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01:00 PM
11-06	UBS Adjusts Price Target on QuidelOrtho to $31 From $26, Maintains Neutral Rating	MT

Evolution of the Average Target: QuidelOrtho Corporation

Evolution of the Target Price: QuidelOrtho Corporation

Changes in Analyst Recommendations: QuidelOrtho Corporation

9d9c66826936ede47dfcccd3fc400.3E_VllP0H6sirLMIWLBTmDnAhfosIx_MByBAXRVEA8A.iy6g8RaAV95S4NRMbf0J0Ajx74NHTkCFa38QOUZ3O_KqDa_vKp5aw337-g~a9da85008dffcaadaf03b2f2fe8178f6

Analysts' recommendations: QuidelOrtho Corporation

11-06	UBS Adjusts Price Target on QuidelOrtho to $31 From $26, Maintains Neutral Rating	MT
11-03	QuidelOrtho Receives FDA 510(k) Clearance for VITROS?? Immunodiagnostic Products hs Troponin I Assay	CI
11-03	Quidelortho receives FDA 510(k) clearance for VITROS Immunodiagnostic Products hs Troponin I assay	RE
10-07	Citigroup Downgrades QuidelOrtho to Neutral From Buy, Adjusts Price Target to $33 From $40	MT
09-03	RBC Raises Price Target on QuidelOrtho to $62 From $60, Keeps Outperform Rating	MT
08-07	UBS Cuts Price Target on QuidelOrtho to $26 From $29, Maintains Neutral Rating	MT
05-08	UBS Cuts Price Target on QuidelOrtho to $29 From $45, Keeps Neutral Rating	MT
02-13	UBS Raises Price Target on QuidelOrtho to $45 From $43, Maintains Neutral Rating	MT
02-13	RBC Trims Price Target on QuidelOrtho to $61 From $64, Keeps Outperform Rating	MT
12-11	Citigroup Upgrades QuidelOrtho to Buy From Neutral, Raises Price Target to $50 From $44	MT
12-10	Jefferies Initiates QuidelOrtho at Hold With $43 Price Target	MT
11-08	UBS Cuts Price Target on QuidelOrtho to $43 From $50, Maintains Neutral Rating	MT
11-08	RBC Capital Adjusts QuidelOrtho Price Target to $64 From $62, Maintains Outperform Rating	MT
19/09/24	UBS Upgrades QuidelOrtho to Neutral From Sell, Adjusts Price Target to $50 From $42	MT
13/09/24	RBC Lifts Price Target on QuidelOrtho to $62 From $61, Keeps Outperform Rating	MT
05/09/24	QuidelOrtho Shares Rise After Craig-Hallum Upgrade	MT
05/09/24	Craig-Hallum Upgrades QuidelOrtho to Buy From Hold, Adjusts Price Target to $57 From $40	MT
24/06/24	RBC Cuts Price Target on QuidelOrtho to $61 From $68, Keeps Outperform Rating	MT
09/05/24	RBC Cuts Price Target on QuidelOrtho to $68 From $81, Keeps Outperform Rating	MT
04/03/24	UBS Downgrades QuidelOrtho to Sell From Neutral, Adjusts Price Target to $42 From $70	MT
14/02/24	William Blair Downgrades QuidelOrtho to Market Perform From Outperform	MT
14/02/24	Craig-Hallum Downgrades QuidelOrtho to Hold From Buy, Adjusts Price Target to $50 From $158	MT
14/02/24	Citigroup Adjusts Price Target on QuidelOrtho to $50 From $72, Maintains Neutral Rating	MT
14/02/24	Raymond James Downgrades QuidelOrtho to Outperform From Strong Buy, Cuts Price Target to $76 From $100	MT
14/02/24	JPMorgan Downgrades QuidelOrtho to Underweight From Neutral, Adjusts Price Target to $37 From $66	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Objective/dr gap
QUIDELORTHO CORPORATION		+30.79%
SARTORIUS AG		+8.7%
ECKERT & ZIEGLER SE	-	+51.83%
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.		+23.02%
REVENIO GROUP OYJ		+26.37%
VAREX IMAGING CORPORATION		+46.88%
CELLAVISION AB		+49.31%
Average		+33.84%
Weighted average by Cap.		+15.26%